Nicotinic acetylcholine receptors (nAchRs) are not only key receptors in the autonomic nervous system, but also are present on immune cells. The alpha seven subunit of nAchR (
alpha7nAchR) suppresses pro-
inflammation in peripheral monocytes by decreasing pro-inflammatory
cytokine production. In spinal cord, alpha7nAchRs are found on microglia, which are known to induce and maintain
pain. We predicted that
alpha7nAchR agonists might attenuate intrathecal HIV-1 gp120-induced, pro-inflammatory
cytokine- and microglia-dependent
mechanical allodynia.
Choline, a precursor for
acetylcholine and selective agonist for
alpha7nAchR, was administered intrathecally either with, or 30 min after, intrathecal gp120.
Choline significantly blocked and reversed gp120-induced
mechanical allodynia for at least 4 h after
drug administration. In addition, intrathecal
choline, delivered either with or 30 min after gp120, reduced gp120-induced IL-1beta
protein and pro-inflammatory
cytokine mRNAs within the lumbar spinal cord. A second
alpha7nAchR agonist,
GTS-21, also significantly reversed gp120-induced
mechanical allodynia and lumbar spinal cord levels of pro-inflammatory
cytokine mRNAs and IL-1beta
protein. A role of microglia is suggested by the observation that intrathecal
choline suppressed the gp120-induced expression of, cd11b, a macrophage/microglial activation marker. Taken together, the data support that
alpha7nAchR may be a novel target for treating
pain where microglia maintain the pro-inflammatory state within the spinal cord.